MX2019012749A - Metodos para tratar trastornos pediatricos. - Google Patents

Metodos para tratar trastornos pediatricos.

Info

Publication number
MX2019012749A
MX2019012749A MX2019012749A MX2019012749A MX2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A MX 2019012749 A MX2019012749 A MX 2019012749A
Authority
MX
Mexico
Prior art keywords
vedolizumab
integrin
beta
alpha
antibodies specific
Prior art date
Application number
MX2019012749A
Other languages
English (en)
Spanish (es)
Inventor
Rosario Maria
A Shetzline Michael
R Treem William
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2019012749A publication Critical patent/MX2019012749A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019012749A 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos. MX2019012749A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
PCT/US2018/029579 WO2018200818A2 (en) 2017-04-28 2018-04-26 Method of treating pediatric disorders

Publications (1)

Publication Number Publication Date
MX2019012749A true MX2019012749A (es) 2020-02-03

Family

ID=62455814

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019012749A MX2019012749A (es) 2017-04-28 2018-04-26 Metodos para tratar trastornos pediatricos.
MX2024012972A MX2024012972A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos
MX2024003905A MX2024003905A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos.
MX2024003906A MX2024003906A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2024012972A MX2024012972A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos
MX2024003905A MX2024003905A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos.
MX2024003906A MX2024003906A (es) 2017-04-28 2019-10-24 Vedolizumab para el tratamiento de pacientes pediatricos.

Country Status (13)

Country Link
US (1) US20200179486A1 (cg-RX-API-DMAC10.html)
EP (1) EP3615071A2 (cg-RX-API-DMAC10.html)
JP (3) JP2020517671A (cg-RX-API-DMAC10.html)
KR (2) KR20190141148A (cg-RX-API-DMAC10.html)
CN (1) CN110612120A (cg-RX-API-DMAC10.html)
AR (1) AR111491A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018256840A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019022268A2 (cg-RX-API-DMAC10.html)
CA (1) CA3061320A1 (cg-RX-API-DMAC10.html)
IL (1) IL270201B2 (cg-RX-API-DMAC10.html)
MX (4) MX2019012749A (cg-RX-API-DMAC10.html)
TW (2) TW202342102A (cg-RX-API-DMAC10.html)
WO (1) WO2018200818A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224280A1 (en) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE366809T1 (de) 1995-02-10 2007-08-15 Millennium Pharm Inc Addressine der schleimhaut und der blutgefässe und ihre verwendung
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1948691A1 (en) 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
EP3978530A1 (en) * 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
MA43755A (fr) * 2016-03-14 2018-11-28 Millennium Pharm Inc Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Also Published As

Publication number Publication date
MX2024012972A (es) 2024-11-08
KR20190141148A (ko) 2019-12-23
RU2019138312A3 (cg-RX-API-DMAC10.html) 2022-02-03
KR20250134146A (ko) 2025-09-09
IL270201B1 (en) 2026-01-01
WO2018200818A2 (en) 2018-11-01
JP2023113655A (ja) 2023-08-16
AU2018256840A1 (en) 2019-11-07
JP2026120554A (ja) 2026-07-22
WO2018200818A3 (en) 2018-12-06
IL270201B2 (en) 2026-05-01
MX2024003906A (es) 2024-04-23
EP3615071A2 (en) 2020-03-04
TW201842932A (zh) 2018-12-16
BR112019022268A2 (pt) 2020-05-19
IL270201A (cg-RX-API-DMAC10.html) 2019-12-31
AR111491A1 (es) 2019-07-17
US20200179486A1 (en) 2020-06-11
RU2019138312A (ru) 2021-05-28
TWI811216B (zh) 2023-08-11
WO2018200818A9 (en) 2019-01-17
TW202342102A (zh) 2023-11-01
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
CN110612120A (zh) 2019-12-24
JP2020517671A (ja) 2020-06-18
MX2024003905A (es) 2024-04-23

Similar Documents

Publication Publication Date Title
MX2024003906A (es) Vedolizumab para el tratamiento de pacientes pediatricos.
DK3731772T3 (da) Systems for the treatment of disease states and disorders
LT3755356T (lt) Kompozicijos, priemonės, sistemos, rinkiniai ir būdai odos ligos būklės gydymui
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EP3644996A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
IL277217A (en) Use of anti-IL-36R antibodies to treat inflammatory bowel disease
SG11201911929XA (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
PL3774897T3 (pl) Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
EP4017489C0 (en) DGD1202 FOR THE TREATMENT OF KRAS-MUTATED CANCERS
EA201990778A1 (ru) Анти-il-33 антитела и их применение
MX380810B (es) Sondas para la proyección de imagen de la proteína huntingtina.
JOP20200231B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
EP4033955A4 (en) IMAGING CATHETER, IMAGING SYSTEM AND METHODS OF OPERATING THEREOF
WO2018067520A3 (en) Therapeutic agents and methods:
EP3504204A4 (en) INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
BR112018000909A2 (pt) imunoconjugados de il22
MX386798B (es) Sondas para la proyección de imagen de la proteína huntingtina.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2017016346A (es) Metodos de tratamiento con taselisib.
EP3829713C0 (en) Adipose Tissue Treatment System
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.